ArticleJournal of neurotrauma2019
Cost-Effectiveness of Biomarker Screening for Traumatic Brain Injury.
Article in Journal of neurotrauma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- The role of spectrin breakdown products in patients with traumatic brain injury: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Salivary Biomarkers as Indicators of TBI Diagnosis and Prognosis: A Systematic Review.Molecular diagnosis & therapy · 2022Pooled it
- Whole-blood point-of-care glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 biomarkers after traumatic brain injury in the US: a prospective diagnostic prediction of intracranial injury on head CT.Lancet regional health. Americas · 2026Article
- GFAP and UCH-L1 for Ruling out Intracranial Lesions After Mild Traumatic Brain Injury: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Advances in biomarkers for predicting outcomes in pediatric neurosurgical hemorrhagic conditions: a narrative review to enhance quality of care.Annals of medicine and surgery (2012) · 2026Review
- Blood-Based Biomarkers for Traumatic Brain Injury: A New Era in Diagnosis and Prognosis.International journal of molecular sciences · 2025Review
- Deciphering the Structural Biology of GFAP: Connotations of Its Potency in Presaging the Diagnosis for Traumatic Brain Injury and AD.Neurology international · 2025Review
- Review
- Budget Impact Analysis of the Use of Specific Biomarkers GFAP and UCH-L1 in the Management of Mild Traumatic Brain Injury in Spain.Journal of clinical medicine · 2025Article
- Hospital-based health technology assessment of a screening rapid test MTBI (GFAP and UCH-L1 blood biomarkers) for mild traumatic brain injury.International journal of technology assessment in health care · 2024Article
- Mitochondria-Targeted Antioxidant Therapeutics for Traumatic Brain Injury.Antioxidants (Basel, Switzerland) · 2024Review
- Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting.Journal of neurotrauma · 2023Article
- Introduction to the Special Section of Neuropsychology Review: Advanced Neuroimaging Findings in Mild Traumatic Brain Injury.Neuropsychology review · 2023Review
- Neuroinflammatory Biomarkers for Traumatic Brain Injury Diagnosis and Prognosis: A TRACK-TBI Pilot Study.Neurotrauma reports · 2023Article
- Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury.IEEE reviews in biomedical engineering · 2023Review
- Status of precision medicine approaches to traumatic brain injury.Neural regeneration research · 2022Review
- Proteomic analysis identifies plasma correlates of remote ischemic conditioning in the context of experimental traumatic brain injury.Scientific reports · 2020Article
- The Role of Blood Biomarkers for Magnetic Resonance Imaging Diagnosis of Traumatic Brain Injury.Medicina (Kaunas, Lithuania) · 2020Review
- Glial Fibrillary Acidic Protein as Biomarker Indicates Purity and Property of Auricular Chondrocytes.BioResearch open access · 2020Article
- Blood Biomarkers for Traumatic Brain Injury: A Quantitative Assessment of Diagnostic and Prognostic Accuracy.Frontiers in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Intracranial hemorrhage after traumatic brain injury (TBI) can be life threatening and requires prompt diagnosis. Computed tomography (CT) scans are a rapid and accurate way to evaluate for hemorrhage. In patients with mild and moderate TBI, however, in whom the incidence of intracranial pathology is low, scanning every patient with CT can be costly. The Food and Drug Administration recently approved a novel biomarker screen, the Banyan Trauma Indicator (BTI), to help streamline the decision for CT scanning in mild to moderate TBI. The BTI screen diagnoses intracranial lesions with a sensitivity and specificity of 97.5% and 99.6%, respectively. We performed cost analyses of the BTI screen to determine the threshold of cost-effectiveness, compared with application of clinical decision rules or routine CT scans, for cases of mild or moderate TBI. With a 0.104 probability of an intracranial lesion in mild TBI, the biomarker screen is cost-effective if the cost is $308.96 or below per test. In moderate TBI, because of the greater prevalence of intracranial lesions at 0.663, there is a lower need for screening, and BTI becomes cost-effective up to $73.41 per test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.